Purple Biotech (PPBT) Interest Income - Net (2021 - 2026)
Purple Biotech (PPBT) posted quarterly Interest Income - Net of -$2.2 million for Q1 2026, down 122.64% year-over-year from $9.7 million in Q1 2025, and down 12800.0% quarter-over-quarter from -$17000.0 in Q4 2025.
Purple Biotech (PPBT) Interest Income - Net (2021 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Interest Income - Net for 6 consecutive years, with -$2.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Income - Net fell 122.64% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at -$3.7 million (down 8.84% YoY), while the FY2025 annual figure was -$1.9 million, up 53.72% from the prior year.
- Interest Income - Net retreated to -$2.2 million in Q1 2026 per PPBT's latest filing, from -$17000.0 in the prior quarter.
- Across five years, Interest Income - Net topped out at -$17000.0 in Q4 2025 and bottomed at -$2.2 million in Q1 2026.
- Historically, Interest Income - Net has averaged -$630529.4 across 5 years, with a median of -$405000.0 in 2023.
- Annual changes were most pronounced in 2023 — Interest Income - Net plunged 396.43% — and 2025, when it soared 96.8%.
- Purple Biotech's Interest Income - Net stood at -$248000.0 in 2022, then plunged by 386.01% to -$1.2 million in 2023, then jumped by 55.86% to -$532000.0 in 2024, then jumped by 96.8% to -$17000.0 in 2025, then slumped by 12800.0% to -$2.2 million in 2026.
- Business Quant data shows PPBT's Interest Income - Net at -$2.2 million in Q1 2026, -$17000.0 in Q4 2025, and -$985000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Income - Net (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Purple Biotech | 130.35 | 130.35 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.19 Mn |
| Dec 31, 2025 | -17,000.00 |
| Mar 31, 2025 | -985,000.00 |
| Dec 31, 2024 | -532,000.00 |
| Mar 31, 2024 | -702,000.00 |
| Dec 31, 2023 | -1.21 Mn |
| Mar 31, 2023 | -278,000.00 |
| Sep 30, 2022 | -248,000.00 |
| Jun 30, 2022 | -89,000.00 |
| Mar 31, 2022 | -56,000.00 |
| Sep 30, 2021 | -68,000.00 |
| Jun 30, 2021 | -78,000.00 |
| Mar 31, 2021 | -118,000.00 |